Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 11/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154949 | 0.99 | LMNA (0.54) | LMNAMAPTL3MBTL1PSEN1PSEN2 | |
| SCHEMBL5316844 | 0.97 | LMNA (0.51) | LMNAMAPTL3MBTL1PSEN1PSEN2 | |
| SCHEMBL5149517 | 0.89 | PSEN1 (0.53) | LMNAMAPTL3MBTL1PSEN1PSEN2 | |
| SCHEMBL5317818 | 0.87 | PSEN1 (0.53) | LMNAMAPTPSEN1PSEN2APH1B | |
| SCHEMBL5151346 | 0.87 | PSEN1 (0.53) | LMNAMAPTL3MBTL1PSEN1PSEN2 | |
| SCHEMBL5151438 | 0.86 | PSEN1 (0.54) | L3MBTL1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5317512 | 0.85 | KDM4E (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5154902 | 0.85 | MCL1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5155238 | 0.85 | PSEN1 (0.51) | MAPTL3MBTL1PSEN1PSEN2APH1B | |
| SCHEMBL5151501 | 0.85 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | claimed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | LMNA 2756/4885MAPT 4617/4885L3MBTL1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.